LZLiqin Zheng

Liqin Zheng

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Liqin Zheng has a total of 25 co-authors. Here are the top co-authors by number of shared publications:

  • Aijun Liu

    Department of Anatomy, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong 510006, PR China

    1 shared publication
  • ChiHung Li

    The International College, Guangzhou University of Chinese Medicine, Guangzhou, China

    1 shared publication
  • ChongZhi OuYang

    Department of Lower Extremity Orthopedics, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou, China

    1 shared publication
  • Chongkai Fang

    Science and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou, China

    1 shared publication
  • Chunmei Ma

    School of Basic Medical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, 510006, China

    1 shared publication
  • Hao Pan

    School of Basic Medical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, 510006, China

    1 shared publication

Latest Publications

  • Open Access

    Light up the mitochondria: Smart tungstate-oligosaccharide nanoplatform orchestrates mitochondrial transfer from M2 macrophages to restore endothelial function for adaptive diabetic wound regeneration

    by Xiuhong Huang, Ziling Lin, Mingshu Ruan, Peizhen Huang, Hongmei Ding, Hao Pan, Jiahui Cao, Chunmei Ma, Qianhao Zhao, Wenping Guo, et al.


  • Open Access

    The sustained-release agent of total flavonoids of Rhizoma drynariae prepared by nano-mesoporous silica can still promote osteogenesis and angiogenesis in vitro

    by XiuHong Huang, ChiHung Li, YiuMan Lau, ZiLing Lin, ChongZhi OuYang, LiQin Zheng

    Total flavonoids of Rhizoma drynariae (TFRD) possess the ability to enhance bone formation by promoting the coupling of angiogenesis and osteogenesis. However, the limited duration of serum concentration necessitates frequent oral administration. Designing TFRD as a sustained-release agent could enhance patient’s compliance and extend efficacy. Mesoporous silica nanoparticles (MSNPs) were used as a carrier for the preparation of a sustained-release agent containing TFRD (TFRD@MSNPs). Material characterization confirmed the successful loading of TFRD onto MSNPs. Subsequently, HUVECs were treated with varying concentrations of TFRD or TFRD@MSNPs to evaluate their effects on proliferation and migration ability. The secretion levels of VEGF, VCAM-1, EGF, TGF-β1, and type H endothelial markers (CD31 and EMCN) were assessed. BMSCs were cultured in conditioned medium derived from HUVECs induced by either TFRD or TFRD@MSNPs to evaluate their osteogenic potential in vitro. Gene expressions of ALP, OCN, and RUNX2, alkaline phosphatase activity, and calcium deposition were measured. The mass fraction of TFRD in the sustained release system TFRD@MSNP was approximately 60%. An appropriate concentration (< 400 µg/mL) of TFRD promoted the proliferation and migration of HUVECs, inhibited the secretion of TGF-β1, and increased the expression levels of VEGF, VCAM-1, EGF, CD31, and EMCN. The conditioned medium from HUVECs induced by TFRD significantly enhanced the osteogenic differentiation potential of BMSCs. An appropriate concentration of TFRD@MSNPs promoted the proliferation and migration of HUVECs, as well as the expression levels of CD31 and EMCN, but had no significant effect on VEGF, VCAM-1, EGF, or TGF-β1 secretion. The conditioned medium from HUVECs induced by TFRD@MSNPs increased ALP, OCN, and RUNX2 gene expression in BMSCs to varying degrees. Compared to the conditioned medium induced by TFRD in HUVECs, the conditioned medium induced by TFRD@MSNPs resulted in more calcium deposits in BMSCs. The sustained-release agent TFRD prepared by MSNPs can effectively promote the osteogenic differentiation of BMSCs through the coupling effect of angiogenesis and osteogenesis in vitro. These findings suggest that using MSNPs to formulate TFRD as sustained-release agent holds potential for clinical application, but the specific mechanism remains to be elucidated.


  • Controllable Adaptive Molybdate‐Oligosaccharide Nanoparticles Regulate M2 Macrophage Mitochondrial Function and Promote Angiogenesis via PI3K/HIF‐1α/VEGF Pathway to Accelerate Diabetic Wound Healing

    by Xiuhong Huang, Liqin Zheng, Yueshan Zhou, Shaonan Hu, Wancheng Ning, Simin Li, Ziling Lin, Shaohong Huang

    The complex wound environment of diabetic wounds leads to poor treatment efficacy, and the inflammatory disorders and vascular injury are the primary causes of death in such patients. Herein, a sprayable, controllable adaptive, pH‐responsive nanosystem of molybdate and oligosaccharide (CMO) is specially developed as an immunomodulatory and angiogenesis‐promotion material for diabetic wound healing. CMO exhibited pH‐responsive release of Mo2+ and oligosaccharide (COS), specifically in response to the alkalescent environment observed in diabetic wounds. CMO provide an anti‐inflammatory environment by promoting M2 polarization through significantly stimulating macrophage mitochondrial function. Specifically, CMO with a certain concentration reduce reactive oxygen species (ROS) and tumor necrosis factor α (TNF‐α) expression, and upregulated mitochondrial membrane potential (MMP), superoxide dismutase (SOD), and interleukin 10 (IL‐10) expression in macrophages. Moreover, CMO facilitate angiogenesis via upregulating the PI3K/HIF‐1α/VEGF pathway—a critical process for the formation of new blood vessels that supply nutrients and oxygen to the healing tissue. Remarkably, CMO promote cell viability and migration of endothelial cells, and enhance the expression of angiogenic genes. In vitro and in vivo studies suggest this simple but powerful nanosystem targeting mitochondrial function has the potential to become an effective treatment for diabetic wound healing.